ISSN 2364-2351 | A 60711 |
Life Sciences and Industry Magazine Spring Edition 2022 | Volume 21 | 20 €
Interview Cellino Biotech CEO Nabiha Saklayen on making cell-based therapies 10x cheaper.
Climate catastrophe
FREE EXCERPT
Saving the planet with biotechnology
Agri-biotech
Capital Markets
COVID-19
Bioprocessing
How deregulating gene editing impacts the organic market
Riding the funding wave in Europe in the pandemic era
How T cells ameliorate the immune response to vaccines
Drugmakers and CDMOs see huge growth in new biologicals
ge bu t y st sin ou ar es r te s d!
aws best of biotech International Biotech & Medtech Start-up Competition
INTRO
European Biotechnology | Spring Edition | Vol. 21 | 2022
FREE EXCERPT
The Next Big Thing: “Biologisation” The development of a sustainable bio-based economy will lead to disruptive economic changes. Venture capitalists focused on targets to drive digitisation in the past are now moving their attention to the bioeconomy. Driven by innovation, changing consumer demand and public support, the transition from a fossil-linear to a bio-based circular economy will speed up. A redefinition of business models and many value chains, or more precisely value circles, are changing the entire economic landscape, step by step. We call it “biologisation”. Despite biologisation being a must to survive on the planet, it comes with a high level of uncertainty, which requires flexibility and a willingness to take risks. A perfect situation for the proliferation of start-ups and the successful investment of venture capital, mainly since most of the bioeconomy markets are enormous. DR MICHAEL BRANDKAMP, is one of the three founders and General Partners of the European Circular Bioeconomy Fund (ECBF) that recently was closed oversubscribed at €300m. Michael and his team’s goal is to speed up the transformation from a fossil-based to a bio-based circular economy in Europe. The German entrepreneur wrote and executed the business plan of HighTech Gründerfonds (HTGF), the most active early-stage fund in Europe, investing in innovative technologies and business models since 2005. As the first managing director, he led HTGF until 2019. Michael has 25 years of experience in investment and management in the venture capital industry.
According to the European Commission, “the bio-based economy or bioeconomy involves the production of renewable biological resources (terrestrial and aquatic) and the conversion of these resources and waste streams into value-added products such as food, feed and bio-based products.” A study by nova-Institute shows strong growth of the large European bioeconomy. A total of 18.6 million people are employed in the various sectors of the bioeconomy and generate a turnover of €2,300bn euros with a growth rate of 25% within one year. So, even moderate shifts in consumer demand lead to significant market volume increases.
Pictures: EBCF
However, bioeconomy investments are not an easy home run. Providing appropriate feedstock sources, production facilities, logistics, and sales in large growing, but sometimes also uncertain high competitive markets make scaling up of companies challenging. In addition, the regulatory framework ischanging for the better but is often uncertain. Therefore, you need excellent execution power, experience, and networks to scale your business and invest successfully in this sector. If you add innovation and a fantastic unique selling position on growing markets, you have chances to meet unicorn potential. In the food industry, you find impressive examples like Oatly valued at approximately €4bn or in the textile recycling industry Renewcell worth around €400m. Investors allocating their capital to venture capital funds learned already that the trade-off between impact and IRR turned to synergy. They consider targets risky without affecting social development goals or aligning to environmental, social and good governance criteria. Therefore, they are open to investing in impact funds to participate in the exciting transformation opportunities to a sustainable bio-based L economy. So, after digitisation, biologisation might be the next big thing.
3
CONTENTS
European Biotechnology | Spring Edition | Vol. 21 | 2022
FREE EXCERPT
INSIGHT EUROPE
COVER STORY
6
Agri-biotech: EU at crossroads for organic farming
10 EU Council greenlights €10bn to create fund for growth 12 Anti-microbial Resistance: The Quiet Pandemic
ECONOMY 24 Interview: Marc Struhalla, CEO, c-Lecta GmbH, Leipzig, Germany: John Dunny, Communications Director, Kerry Group plc, Tralee, Ireland
68 Central Europe: Germany, Switzerland and Austria 70 Southern Europe: Italy, Portugal, and Spain 72 Eastern Europe: Poland, Lithuanian and the Czech Republic
SPOTLIGHT 74 Nation profile: Biotech in Denmark
SCIENCE & TECHNOLOGY
26 SIX opens Sparks segment 28 Analyst commentary
14
CO2 – saving the world with biotech In the first week of March, the news hit that 75% of the Amazon rainforest is on the verge of irreversible destruction, coupled with a call from the authors of the IPCC’s 6th Assessment Report (Part II) to immediately limit human-made greenhouse gas emissions. Despite the urgency of the situation, politicians still prefer subsidising farmers to funding biotech entrepreneurs. Companies meanwhile are churning out products that could help relieve some of the stress on natural cycles. Biotechnological solutions can help save the world. But we have to act fast.
29 European Biotech Stocks 32 Interview: Matthias Schulze, Dir. Marketing OEM Components & Instrumentation, Coherent Inc 34 Update on clinical trials 36 Start-up: Amsilk GmbH
76 3D culture: what makes the tumour grow; Artificial neurons; Message in a bottle; Poison from the water 78 T cells ameliorate immune response to SARS-CoV-2 80 Ultra-low cold storage environment
PICK & MIX
38 EMA update
REGIONAL NEWS 64 Northern Europe: Sweden, Denmark, Norway and Finland 66 Western Europe: France, Belgium, The Netherlands and the UK
82 Biopeople/Product 83 News from our partner associations 88 Company index 89 Events 90 Encore
IMPRINT European Biotechnology (ISSN 2364-2351) is published quarterly by: BIOCOM AG, Jacobsenweg 61, D-13509 Berlin, Germany, Tel.: +49-30-264921-0, Fax: +49-30-264921-11, Email: service@ european-biotechnology.com, Internet: www.european-biotechnology.com; Publisher: Andreas Mietzsch; Editorial Team: Thomas Gabrielczyk (Editor in Chief), Derrick Williams (Co-editor), Dr Georg Kääb, Maren Kühr; Advertising: Oliver Schnell, +49-30-264921-45, Christian Böhm, +49-30-264921-49, Andreas Macht, +49-30-264921-54; Distribution: Lukas Bannert, +49-30-264921-72; Graphic Design: Michaela Reblin; Production: Martina Willnow; Printed at: Königsdruck, Berlin; European Biotechnology Life Sciences & Industry Magazine is only regularly available through subscription with a BIOCOM CARD. Annual subscription BIOCOM CARD Europe: €80 for private individuals (students €40) incl. VAT, €120 plus VAT for corporates. Prices includes postage & packaging. Ordered subscriptions can be cancelled within two weeks directly at BIOCOM AG. The subscription is initially valid for one calendar year and is automatically renewed every year after. The subscription can be cancelled at any time and is valid until the end of that calendar month. Failures of delivery, which BIOCOM AG is not responsible for, do not entitle the subscriber to delivery or reimbursement of pre-paid fees. Seat of court is Berlin, Germany. As regards contents: individually named articles are published within the sole responsibility of their respective authors. All material published is protected by copyright. No article or part thereof may be reproduced in any way or processed, copied, and proliferated by electronic means without the prior written consent of the publisher. Supplement: EuroJobsites Ltd; Cover Photo: AdobeStock_ Kwest; ® BIOCOM is a registered trademark of BIOCOM AG, Berlin, Germany.
Picture: AdobeStock_ Kwest
4
CONTENTS
European Biotechnology | Spring Edition | Vol. 21 | 2022
FREE EXCERPT
FINANCING
GENOME EDITING
EDITORIAL
The right priorities
Money follows ideas It should come as no surprise that health innovation investment has been hot during the pandemic. It’s skyrocketed worldwide, and also risen strongly in Europe. But when it comes to financing biotech innovation in healthcare, an analysis shows that only a few countries are really leaping forward, and that a lot of the new funding is concentrated in post-Brexit Britain.
6
Europe at a crossroads
40
Europe’s front against the use of genome editing in agriculture is becoming increasingly fragile in view of the prospect of greater sustainability and climate protection through the use of biotechnology. In Germany, too, discussions are already taking place behind the scenes.
Pictures: AdobeStock_Evgeniia (left), iStock_wildpixel (right); Rainer Mirau (left above), BIOCOM AG (right)
SPECIAL Bioprocessing 47 Booming market 50 C linical trials data – mastering the data revolution 52 Lead optimisation – the sequence is the key 54 Interview Cellino Biotech 58 RTSM benefits 60 A new protein purification workflow 61 Gene therapy update
For the second year in a row, fateful events have distracted the world’s attention from the rapid advance of climate change – and how the determined deployment of the right biotechnology solutions in construction, agriculture and industrial production could massively curb the 80% of greenhouse gas emissions generated by G20 countries (see p. 14). The pandemic had already put the spotlight on biotech innovations. But the focus has shifted now to the autocrat sacrificing young men in war in his pursuit of power. Everyone was looking to Ukraine when the Intergovernmental Panel on Climate Change declared in its 6th Assessment Report the importance of finally getting serious about limiting the rise in global temperatures – precisely what the G20 countries are not doing. Contrary to public pronouncements, they are not pursuing a post-pandemic green reconstruction. Of the US$14 trillion invested over the past 24 months, just 6% was emissions-reducing. And it should be so simple. What triggered a fountain of funding for COVID-19 (see p. 40) could do the same for climate protection. Despite the smoke and mirrors on the part of some companies when it comes to bio-based circularity and greenwashing, effective biotech solutions are now on the cusp of market entry in a wide range of fields.
Thomas Gabrielczyk Editor-in-Chief
5
BIOTECH PRODUCTION
European Biotechnology | Spring Edition | Vol. 21 | 2022
Pictures: xxx
14
INDUSTRIAL BIOTECH
European Biotechnology | Spring Edition | Vol. 21 | 2022
FREE EXCERPT
CO2 – saving the world with biotech The news that 75% of the Amazon rainforest is on the verge of irreversible destruction came in March, along with a call from the authors of the IPCC’s 6th Assessment Report to immediately limit human-made CO2 emissions. Unlike politicians who – under the no-longertimely creed of Jobs and Growth – prefer to subsidise farmers rather than biotech entrepreneurs, industrial biotech players are already churning out products that could relieve stress on natural cycles. CLIMATE CHANGE
C
limate researchers appeared before the global public at the end of February to repeat what they say has fallen on deaf ears among politicians for years. “Our window of opportunity is shrinking,” said HansOtto Pörtner, co-chair and lead author of the 6th IPCC Assessment Report. It highlights the already visible and future consequences of rising temperatures, which have so far increased an estimated 1.1°C compared to preindustrial levels. The decisive factor now, he says, is to set the course over the next ten years to keep the greenhouse gas (GHG)-induced rise below 1.5°C. “Policymakers are struggling to do the right thing,” Pörtner stressed – but they aren’t doing it fast enough.
Pictures: BASF SE (left); PIK Potsdam (right)
Time to act now Driven by global warming, ocean acidification, droughts and associated weather extremes, 50% of all species are now shifting polewards, which endangers existing ecosystems. According to the report, vector-borne diseases are also spreading north and south. In other words, the COVID-19 pandemic might have been just a precursor for the climate- caused health threats to come. Several co-authors of the report noted that around 3.5 billion people will be hit very hard, and conflicts over water and land are foreseeable if no decisive and internationally coordi-
nated countermeasures are taken immediately. Chris Boulton from the University of Exeter and his colleagues say long-term satellite remote sensing data demonstrate
KATJA FRIELER Co-Author 6th IPCC Asessment Report, Potsdam Institute for Climate Impact Research, Germany
? !
Is there still a chance to curb global climate change?
”We are leaving the world as we know it. Our report shows that the observed climate impacts are increasing across the board. All of this is already happening today, with a warming of only 1.1°C – which clearly shows that we urgently need to limit further temperature increases. This is not about environmental issues, it is about our own security.
that too little decisive action has been taken so far. They reported at the beginning of March that three-quarters of the Amazon rainforest – an important carbon sink at the planetary level – is at imminent threat of destruction, even if the signs of it are not outwardly obvious (doi: 10.1038/ s41558-022-01287-8). The report is carefully worded: “the Amazon rainforest is likely losing resilience”. Coupled, however, with data from Brazilian climate researcher Luciana Gatti, it actually confirms for the first time that the Amazon rainforest now emits more carbon dioxide than it can absorb (10.1038/s41586-021-03629-6) – a gigatonne of CO2 per year, to be exact. “To achieve net zero by 2050, we must cut emissions every year by an amount comparable to that seen during the COVID-19 pandemic,” said Pierre Friedlingstein, lead researcher of the Global Carbon Project at the COP26 Climate Conference in Glasgow last November. However, his proposal for cutting global GHG emissions “by about 1.4 billion tonnes each year on average” is far less than the nearly 400 Gt of CO2 equivalents that the IPPC says the world would still be allowed to release into the atmosphere to keep temperatures at +1.5°C. That now seems likely to happen within a decade. The call by lead authors of the IPCC report to use coordinated communication campaigns to inform ›› Read the full story in the printed issue.
15
RUBRIK
European Biotechnology | Spring Edition | Vol. 21 | 2022
Pictures: xxx
40
INNOVATION
European Biotechnology | Spring Edition | Vol. 21 | 2022
FREE EXCERPT
Money follows ideas It should come as no surprise that health innovation investment has been hot during the pandemic. It’s skyrocketed worldwide, and also risen strongly in Europe. But when it comes to financing biotechnology innovation in healthcare, an analysis shows that only a few countries are really leaping forward, and that a lot of the new funding is concentrated in post-Brexit Britain. Cash-rich, deep-pocketed venture financiers say that paradigm needs to change, and are calling for new approaches. INVESTMENT
T
he success story of the Pfizer/Biontech ‘Made in Germany’ mRNA vaccine has helped efforts to get the pandemic at least somewhat under control, even if the situation remains precarious in many parts of the world. Since early 2020, vast sums have been funnelled not only into vaccine development, but also developing therapeutics and many other areas of medicine. Governments in the US, Europe and other countries have thrown billions at special programmes and initiatives, accelerating discoveries and impacting historically on healthcare. One result of these billion-dollar transfers is that many private investors have now also developed a fresh interest in healthcare sector innovation. That’s re-
flected by a sharp increase in financial volumes of European venture funds in the segment (see table below).
Unprecedented cash injection In 2021 the UK-based Abingworth Fund got things rolling in February when its Bioventure Fund 8 set the bar high with a volume of around €390m. Then Sofinnova Partners from France in March beat that score handily with €445m. The Forbion Growth Opportunities Fund I closing soon after brought in a very respectable €360m, and in May Abingworth surpassed itself, closing the Clinical CoDevelopment Fund (ACCD 2) for its new record (€476m). But the geyser of money is most visible at GHO Capital (Glob-
al Healthcare Opportunities), a Londonbased global healthcare investor that announced the closing of its third fund (GHO Capital III LP) for an all-time high of €2bn, doubling the amount reached by its predecessor in just two years. The soaring sums were making even some investors dizzy, but instead of slowing, things soon hit an even more frantic pace. French-based Jeito Capital reported €534m in September, then Sofinnova also topped itself for the second time in a year with another fund (€472m) in October. And finally, in November, Dutch LSP took the EU-European venture crown with its largest ever closed fund (€850m; now €1bn in 2022). This shortlist is just an overview of toptier earners, and is by no means exhaus-
Picture: AdobeStock_Evgeniia
Major Biotech VC Fund closings in 2021 (*)
Fund name
Organisation
Closing Date
Volume (Mio. Euro)
› Abingworth Bioventure Fund 8
Abingworth LLP
February 2021
390
United Kingdom
› Sofinnova Crossover Fund
Sofinnova Partners
March 2021
445
France
› Forbion Growth Opportunities Fund I
Forbion
April 2021
360
The Netherlands
› Abingworth Clinical Co-Development Fund
Abingworth LLP
May 2021
476
United Kingdom
› GHO Capital III LP
GHO Capital
July 2021
2,000
United Kingdom
› Jeito I
Jeito Capital
September 2021
534
France
› Sofinnova Capital X
Sofinnova Partners
October 2021
472
France
› LSP Flagship Fund 7
LSP (now EQT Life Science)
November 21/Feb 22
› M Ventures III
Merck KGaA
December 2021
600
Germany
› European Circular Bioeconomy Fund I
ECBF
December 21/February 2022
300
Luxembourg/Germany
1,000
Country
The Netherlands
›› Read the full story in the printed issue.
41
88
COMPANY INDEX
European Biotechnology | Spring Edition | Vol. 21 | 2022
FREE EXCERPT
10x Genomics (NL) . . . . . . . . . . . . . . . . . 57 2cureX AB (SE). . . . . . . . . . . . . . . . . . . . . 72 4GClinical (NL) . . . . . . . . . . . . . . . . . 49, 59 Abingworth LLP (GB). . . . . . . . . . . . . . . . 41 Abivax AB (F). . . . . . . . . . . . . . . . . . . . . . 90 Adjuvant Capital (USA). . . . . . . . . . . . . . . 69 Aelis Farma SA (F). . . . . . . . . . . . . . . . . . . 67 Agritech Biotalys (IT) . . . . . . . . . . . . . . . . 70 Aleph Farms (IL). . . . . . . . . . . . . . . . . . . . 21 Allogene Therapeutics Inc. (USA). . . . . . . 56 Almirall S. A. (ES). . . . . . . . . . . . . . . . . . . 71 Altermune Technologies LLC (USA) . . . . . 67 Amsilk GmbH (DE). . . . . . . . . . . . . . . . . . 36 Animatrix Founders LLP (GB). . . . . . . . . . 67 Aphea.Bio NV (B). . . . . . . . . . . . . . . . . . . 44 Arthur Steinmetz Beteiligungs GmbH (DE). . . . . . . . . . . . . . 25 Asabys Partners (ES) . . . . . . . . . . . . . . . . . 63 Atai Life Sciences AG (DE). . . . . . . . . . . . 42 Austrian Business Agency. . . . . . . . . . 72, 73 Avantium Life Sciences BV (NL). . . . . . . . 20 B Medical Systems (LU) . . . . . . . . . . . . . . 92 BASF SE (DE) . . . . . . . . . . . . . . . . . . . . . . 20 Bavarian Nordic A/S (DK). . . . . . . . . . 28, 34 Baxter Holding BV. . . . . . . . . . . . . . . . . . 38 Bayer AG (DE) . . . . . . . . . . . . . . . 34, 48, 54 BerGenBio AS (NO). . . . . . . . . . . . . . . . . 34 Biocat, The BioRegion of Catalonia. . . . . . 71 BIOCOM AG (DE) . . . . . . . 22-23, 39, 43, 87 BioEcho Life Sciences GmbH (DE). . . . . . 77 BioGenes GmbH (DE) . . . . . . . . . . . . . . . 61 Biomason (USA). . . . . . . . . . . . . . . . . . . . 21 Biontech SE (DE). . . . . . . . . . . . . . 35, 41, 47 Biosyntia (DK) . . . . . . . . . . . . . . . . . . . . . 68 BlueRock Therapeutics Inc. (USA). . . . . . . 34 Bluu Seafood GmbH (DE). . . . . . . . . . . . . 21 Boehmert & Boehmert (DE) . . . . . . . . . . . 11 Boehringer Ingelheim Venture Fund (DE) . 67 Bolz-Intec (DE). . . . . . . . . . . . . . . . . . . . . 19 Brain AG (DE). . . . . . . . . . . . . . . . . . . . . . 21 Bristol Myers Squibb (USA). . . . . . . . . . . . 66 c-LEcta GmbH (DE) . . . . . . . . . . . 21, 24, 25 CANDOR Bioscience GmbH (DE) . . . . . . 21 Canica (CH/NO). . . . . . . . . . . . . . . . . . . . 64 Capricorn Sustainable Chemistry Fund (B).25 Carbios SAS (F). . . . . . . . . . . . . . . . . . . . . 44 Cellectis SA (F). . . . . . . . . . . . . . . . . . . . . 56 Cellino Biotech Inc. (USA). . . . . . . . . 48, 54 Centauri Therapeutics Ltd. (GB) . . . . . . . . 67 Centessa Pharmaceuticals plc (GB). . . . . . 42 Choose New Jersey (USA). . . . . . . . . . . . . 13 Codagenix (USA) . . . . . . . . . . . . . . . . . . . 78 Coherent Inc. (CN). . . . . . . . . . . . . . . . . . 32 Coherent Shared Services B.V. (DE). . . . . . 32 Crispr Therapeutics (CH). . . . . . . . . . . . . . 56 Cubiq Foods srl (ES) . . . . . . . . . . . . . . . . . 21 Curevac N.V. (DE). . . . . . . . . . . . . . . . . . . 34 Cytovation AS (NO) . . . . . . . . . . . . . . . . . 64 DNA Script SAS (F). . . . . . . . . . . . . . . . . . 42 Dr. Bader Beteiligungs GmbH (DE). . . . . . 25 EBD Group (USA). . . . . . . . . . . . . . . . . . . 81 Egle Therapeutics SAS (F) . . . . . . . . . . . . . 66 Elicit Plant SAS (F) . . . . . . . . . . . . . . . . . . 44 Enthera Pharmaceuticals (IT). . . . . . . . . . . 71 Eppendorf Austria GmbH. . . . . . . . . . . . . 17 EQT Life Sciences (DK/SE) . . . . . . . . . 41, 66 eurobiotechjobs.net (B). . . . . . . . . . . . 31, 91 EuroJobsites Ltd (GB) . . . . . . . . . Supplement European Biotechnology Network (B). . . . 85 Evommune Inc. (USA) . . . . . . . . . . . . . . . 66 Evotec SE (DE) . . . . . . . . . . . . . . . . . . . . . 67
Excelya Group SAS (F) . . . . . . . . . . . . 30, 55 Exscientia Ltd. (GB) . . . . . . . . . . . . . . . . . 42 FGK Clinical Research GmbH (DE). . . . . . 59 Flow Eighteen38 (PT). . . . . . . . . . . . . . . . 71 Fördergesellschaft IZB (DE). . . . . . . . . . . . 37 Forbion Capital Partners (NL) . . . . . . . . . . 41 Formo GmbH (DE). . . . . . . . . . . . . . . . . . 21 Fresenius Medical Care Ventures (DE). . . . 69 Future Meat (IL) . . . . . . . . . . . . . . . . . . . . 21 Galapagos NV (B). . . . . . . . . . . . . . . . . . . 82 Genenta Science (IT) . . . . . . . . . . . . . . . . 70 GenIBET (PT) . . . . . . . . . . . . . . . . . . . . . . 65 Genmab A/S (DK). . . . . . . . . . . . . . . . . . . 75 Genscript (USA). . . . . . . . . . . . . . . . . . . . 58 GHO Capital (GB) . . . . . . . . . . . . . . . . . . 41 Gilde Healthcare Partners (NL). . . . . . 63, 70 GlaxoSmithKline (GB) . . . . . . . . . . . . 34, 66 Gourmey SAS (F) . . . . . . . . . . . . . . . . . . . 21 Grand Pharmaceuticals (CN) . . . . . . . . . . 68 Gyroscope Therapeutics Holdings plc. . . . 67 Hadean Ventures (NO). . . . . . . . . . . . . . . 69 Heidelberg Pharma AG (DE). . . . . . . . . . . 35 Helicase Venture (USA) . . . . . . . . . . . . . . 69 High Tech Gründerfonds GmbH (DE). . . . 24 HotSpot Therapeutics Inc. (USA). . . . . . . . 66 Hovione SA (PT). . . . . . . . . . . . . . . . . . . . 82 Human Cell Design SAS (F) . . . . . . . . . . . 66 IBF (DK). . . . . . . . . . . . . . . . . . . . . . . . . . 21 ICON Clinical Research , Inc. (USA). . . . . 53 Idorsia Pharmaceuticals Deutschland. . . . 38 ImCheck SA (F). . . . . . . . . . . . . . . . . . . . . 34 Immunocore Ltd. (IRL) . . . . . . . . . . . . . . . 38 Impilo (SE) . . . . . . . . . . . . . . . . . . . . . . . . 64 Index Pharmaceuticals AB (SE). . . . . . . . . 82 Indivumed GmbH (DE). . . . . . . . . . . . . . . 26 Informa Markets / CPhI 2022 (NL) . . . . . . 46 InOvo NV (NL). . . . . . . . . . . . . . . . . . . . . 44 Integra Therapeutics (ES). . . . . . . . . . . . . . 82 Intellia Therapeutics (USA). . . . . . . . . . . . 61 IO Biotech ApS (DK). . . . . . . . . . . . . . . . . 42 Isotope Technologies Munich (DE) . . . . . . 68 Ivy Farm Ltd. (GB). . . . . . . . . . . . . . . . . . . 21 Jeito Capital (F). . . . . . . . . . . . . . . . . . . . . 41 Kent Life Science LLP (GB). . . . . . . . . . . . 67 Kerry Group (IRL). . . . . . . . . . . . . 21, 24, 25 KfW Bankengruppe (DE). . . . . . . . . . . . . . 25 LAK Holdings LLP (GB). . . . . . . . . . . . . . . 67 Lansdowne Partners (GB) . . . . . . . . . . . . . 69 LANXESS Deutschland GmbH. . . . . . . . . 71 LanzaTech (USA) . . . . . . . . . . . . . . . . . . . 20 Life Science Austria LISA . . . . . . . . . . . . . . 2 Lonza AG (CH). . . . . . . . . . . . . . . . . . . . . 47 Lowenco A/S (DK) . . . . . . . . . . . . . . . . . . 64 Loxbridge Research LLP. . . . . . . . . . . . . . 67 Lumicks NV (NL) . . . . . . . . . . . . . . . . . . . 62 MacBrooks Exhibitions/Chemspec (GB). . . . . 63 Marinomed Biotechnologie GmbH (AT). . 69 Matrica (IT). . . . . . . . . . . . . . . . . . . . . . . . 71 Meatable (NL). . . . . . . . . . . . . . . . . . . . . . 21 Meissa Biotech (USA). . . . . . . . . . . . . . . . 78 Memo Therapeutics AG (DE). . . . . . . . . . . 69 Merck KGaA (DE). . . . . . . . . . . . . . . . . . . 41 Messe München GmbH (DE) . . . . . . . . . . 33 MFT Mittelstands-Fonds Thüringen (DE). . 25 MICA Biosystems (GB). . . . . . . . . . . . . . . 63 Mirai Foods AG (CH) . . . . . . . . . . . . . . . . 21 Moderna Inc. (USA). . . . . . . . . . . . . . 35, 47 Molecular Partners AG (CH). . . . . . . . . . . 34 MosaMeat NV (NL). . . . . . . . . . . . . . . . . . 21 Mylan Ireland Ltd. . . . . . . . . . . . . . . . . . . 38 Neurimmune AG (CH). . . . . . . . . . . . . . . 69
New Enterprise Associates (USA) . . . . 63, 70 Nordic Nanovector AS (NO). . . . . . . . . . . 64 NorthSea Therapeutics BV (NL). . . . . . . . . 34 Novartis AG (CH). . . . . . . . . . . . . 63, 67, 70 Novavax Inc. (USA) . . . . . . . . . . . . . . . . . 38 Novo Holdings (DK). . . . . . . . . . . . . . . . . 67 Novo Nordisk A/S (DK). . . . . . . . . . . . 65, 75 Novozymes A/S (DK) . . . . . . . . . . . . . . . . 75 Nuritas Ltd. (IRL). . . . . . . . . . . . . . . . . . . . 44 Oasmia Pharmaceutical AB (SE). . . . . . . . 65 Oncoarendi Therapeutics SA (PL). . . . . . . 82 ONK Therapeutics Ltd. (IRL). . . . . . . . . . . 61 Ono Pharmaceutical Co. Ltd (JP) . . . . . . . 69 Otsuka Pharmaceutical (JP). . . . . . . . . . . . 66 Owkin Inc. (F) . . . . . . . . . . . . . . . . . . . . . 42 Oxford Nanopore Technologies Ltd. (GB). 42 Oxurion NV (B) . . . . . . . . . . . . . . . . . . . . 35 Peace of Meat (IL). . . . . . . . . . . . . . . . . . . 21 PeelPioneers B.V. (NL) . . . . . . . . . . . . . . . 44 Perlan Technologies (PL). . . . . . . . . . . . . . 72 Pfizer Inc. (USA). . . . . . . . . . . . . . 41, 47, 66 PhoreMost (GB) . . . . . . . . . . . . . . . . . . . . 82 PlasmidFactory GmbH & Co. KG (DE) . . . 35 Premier Research (USA). . . . . . . . . . . . . . . 7 Prolupin GmbH (DE) . . . . . . . . . . . . . . . . 44 Promedica Prague Group (CZ). . . . . . . . . 72 Protix BV (NL) . . . . . . . . . . . . . . . . . . . . . 44 Quell Therapeutics Ltd. (GB). . . . . . . . . . . 42 Quest for Growth (NL). . . . . . . . . . . . . . . 25 Recipharm AB (SE). . . . . . . . . . . . . . . . . . 65 Rentschler Biopharma SE (DE) . . . . . . 47, 51 Ribbon Biolabs (AT). . . . . . . . . . . . . . . . . 69 Roche AG (CH). . . . . . . . . . . . . . . . . . . . . 68 RoosterBio Inc. (USA). . . . . . . . . . . . . . . . 61 Rovi Pharmaceuticals (ES). . . . . . . . . . . . . 47 Sandwater (NO). . . . . . . . . . . . . . . . . . . . 64 Sanofi-Aventis (F). . . . . . . . . . . . . . . . . . . 38 Servier (F). . . . . . . . . . . . . . . . . . . . . . . . . 56 Sharp (NL) . . . . . . . . . . . . . . . . . . . . . . . . 63 Shougang Group (CN) . . . . . . . . . . . . . . . 20 SHS GmbH (DE). . . . . . . . . . . . . . . . . 25, 64 Sino Biological Europe GmbH (DE) . . . 9, 88 Sofinnova Partners (F). . . . . . . . . . . . . . . . 41 Solar Foods (FIN) . . . . . . . . . . . . . . . . . . . 65 Sotio a.s. (CR). . . . . . . . . . . . . . . . . . . . . . 42 SpliceBio S.L. (ES). . . . . . . . . . . . . . . . 63, 70 Super Meat (IL). . . . . . . . . . . . . . . . . . . . . 21 Swiss Biotech Association SBA. . . . . . . . . 27 UCB Ventures (B). . . . . . . . . . . . . . . . 63, 70 Univercells Technology NV . . . . . . . . . . . 61 Vaccitech Ltd. (GB). . . . . . . . . . . . . . . . . . 42 VALIDOGEN GmbH (AT). . . . . . . . . . . . . 62 VBI Vaccines BV (USA). . . . . . . . . . . . . . . 38 Vector Biopharma AG (CH) . . . . . . . . . . . 62 Versalis (IT). . . . . . . . . . . . . . . . . . . . . . . . 71 Verve Ventures (CH). . . . . . . . . . . . . . . . . 69 Vesalius Biocapital Partners S.a (LU). . . . . 69 Vetter GmbH & Co. KG (DE) . . . . . . . . . . 79 Vir Therapeutics (USA). . . . . . . . . . . . . . . 34 Vital Meat (F). . . . . . . . . . . . . . . . . . . . . . 21 Vivesto AB (SE). . . . . . . . . . . . . . . . . . . . . 65 Wacker Biotech GmbH (DE). . . . . . . . . . . 68 Warning Beteiligungs GmbH (DE) . . . . . . 25 WntResearch (SE). . . . . . . . . . . . . . . . . . . 82 Wren Capital (USA) . . . . . . . . . . . . . . . . . 67 Xlife Sciences AG (CH). . . . . . . . . . . . . . . 26 Ysios Capital Partners (ES). . . . . . . . . . 63, 70 YUMAB GmbH (DE). . . . . . . . . . . . . . 30, 60 Zaklady Farmaceutyczne Polpharma . . . . 38 Zealand Pharmaceuticals A/S (DK). . . . . . 75 Zürcher Kantonalbank (CH). . . . . . . . . . . 69
stock.adobe.com/annette shaff
New job? Need help hunting?
eurobiotechjobs.net
Temperature
-86°C to -20°C
Green Refrigerants
Ambient temp.
+10°C to +43°C
NEW DIN 58375
U201
U401
U501
U701
U901
232 / 217
478 / 454
634 / 602
791 / 751
949 / 900
Vials storage capacity (2ml)
15000
34500
46000
57500
69000
Cryoboxes storage capacity
150 (model H50)
345 (model H50)
460 (model H50)
575 (model H50)
690 (model H50)
Reliable Adjustable set point from -86°C to -20°C
•
Uniform temperature distribution
•
Fast door opening recovery times
•
Extended hold over times
•
24*7 remote monitoring via RTMD and °B Connected (in compliance with 21 CFR Part 11, subpart A & B)
Convenient
•
Use natural refrigerants and are in line with EU F-Gas and US SNAP regulations
•
Ideal for the safe storage of various COVID-19 vaccines requiring storage temperatures below -20°C
•
Insulated inner doors, high quality sealed gaskets, and high quality insulation
•
7’’ touchscreen easily accessible via the bar on the door
•
•
Certified class II medical devices (EU MDR and US FDA)
Password protected - NFC based locking
•
Modular interior equipment
•
Energy Star certification available for the 60Hz U701 & U901 models
•
High-quality stainless steel and other material for extended life spans
L ICA DE
E VIC
MED
•
Sustainable
45
Gross / Net volume (l)
(E
U ) C e r t i f i ed 7 2 017 /
B Medical Systems is a global manufacturer of medical-grade refrigeration and transport solutions with over 40 years of experience. B Medical Systems S.à r.l. | 17, op der Hei L-9809 Hosingen, Luxembourg | Tel.: (+352) 92 07 31-1 | info@bmedicalsystems.com
www.bmedicalsystems.com